Financial Performance - Vicarious Surgical reported an adjusted net loss of $15.3 million for Q1 2025, equating to an adjusted loss per share of $2.58, compared to an adjusted net loss of $15.1 million and a loss per share of $2.58 in Q1 2024[6]. - The GAAP net loss for Q1 2025 was $15.4 million, or $2.60 per share, compared to a GAAP net loss of $17.0 million, or $2.90 per share, in Q1 2024[6]. - The company had a comprehensive net loss of $15.4 million for Q1 2025, compared to a comprehensive net loss of $17.1 million in Q1 2024[16]. Operating Expenses - The company's total operating expenses for Q1 2025 were $15.7 million, a decrease of 2% from $16.1 million in the same period last year[6]. - Research and development expenses for Q1 2025 were $9.4 million, down from $10.0 million in Q1 2024[6]. Cash Position - Cash and investments as of March 31, 2025, totaled $37.4 million, with a cash burn rate of $11.7 million for the first quarter[6]. - Vicarious Surgical expects a full-year cash burn of approximately $50 million for 2025[5]. Assets and Deficit - Total assets decreased from $67.7 million as of December 31, 2024, to $55.1 million as of March 31, 2025[18]. - Vicarious Surgical's accumulated deficit increased to $211.3 million as of March 31, 2025, from $195.9 million at the end of 2024[18]. Clinical Milestones - The company is on track to achieve its first clinical patients within the next few quarters, marking a significant milestone in its transition to a clinical-stage company[3].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 100 Campus Drive, 6th Floor Marlborough, Massachusetts 01752 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-42541 NEWHOLD INVESTMENT CORP III (Exact name of registrant as specified in its charter) | Cayman Islands | 32-0781832 ...

Production and Sales - Gold Resource Corporation produced and sold a total of 18,580 gold equivalent ounces in 2024, comprising 8,598 gold ounces and 817,333 silver ounces, with average prices of $2,354 and $28.75 per ounce respectively[11]. - Gold Resource Corporation focuses on gold and silver production, with operations centered on the Don David Gold Mine in Oaxaca, Mexico[19]. Financial Performance - The company reported a cash and cash equivalent balance of $1.6 million as of December 31, 2024, a decrease of $4.6 million from the previous year, primarily due to capital investments of $6.4 million and operating cash outflows[11]. - Working capital decreased by 86% to $2.1 million from $15.2 million in 2023, driven by a decline in cash balance and lower annual gold production[11]. - Total cash costs per gold equivalent ounce sold were $2,330, while total all-in sustaining costs were $2,939[11]. - The company raised $2.5 million through a registered direct offering and $3.0 million through its ATM Program in early 2025 to support its financial needs[12]. Capital Expenditures and Development Plans - The company requires approximately $7.0 million for additional mining equipment and mill upgrades, along with $8.0 million in working capital over the next 12 months for initial development[10]. - The company plans to secure a third filter press to increase processing throughput from 1,300 tonnes/day to 1,500 tonnes/day, which is expected to significantly impact profitability due to fixed costs[5]. - Future development plans include the Back Forty Project in Michigan, USA[19]. - The company is negotiating with a contractor to develop and produce from the Three Sisters vein system, with operations expected to start in April 2025[5]. Safety and Operational Efficiency - The company achieved an Accident Free Full Year with a lost time injury frequency rate of zero, reflecting the effectiveness of its safety program[5]. - The exploration program successfully increased the potential resources and confidence in the Three Sisters vein system, despite suspending exploration drilling in August 2024 to conserve cash[6]. Strategic Initiatives and Leadership - The company has a dedicated leadership team to guide its strategic initiatives and operational goals[19]. - The company is currently negotiating with contractors and acquiring equipment, which are critical for its operations[20]. - Anticipated near-term capital needs and potential sources of capital are being evaluated[20]. - The company expects to maintain cash flow and productivity levels to support ongoing operations[20]. - There are risks and uncertainties associated with the company's forward-looking statements, which may affect actual results[20]. - The company will continue to file periodic reports with the SEC, providing updates on its financial status and operational performance[20]. Contact Information - For further inquiries, the Chief Financial Officer can be contacted directly[21].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35633 Sound Financial Bancorp, Inc. (Exact name of registrant as specified in its charter) | Maryland | 45-5188530 | | --- | -- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Minnesota 90-0316651 (State or other jurisdiction of incorporation or organization) FORM 10-Q __________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________________ to ___________________ ...

Financial Performance - Hertz reported total revenues of $1.813 billion for Q1 2025, a decrease of 13% compared to $2.080 billion in Q1 2024[23] - Adjusted net income for Q1 2025 was a loss of $346 million, an improvement of 12% compared to a loss of $392 million in Q1 2024[23] - Revenues for Q1 2025 were $1,813 million, a decrease of 12.8% compared to $2,080 million in Q1 2024[35] - Net loss for Q1 2025 was $443 million, compared to a net loss of $186 million in Q1 2024, indicating a worsening of 138%[35] - Total revenues for Hertz Global Holdings decreased to $1,813 million in Q1 2025 from $2,080 million in Q1 2024, representing a decline of approximately 12.8%[42] - Adjusted Net Income for Q1 2025 was a loss of $346 million, compared to a loss of $392 million in Q1 2024, showing an improvement of 11.7%[45] - Adjusted Corporate EBITDA for Q1 2025 was a loss of $325 million, compared to a loss of $567 million in Q1 2024, indicating a significant improvement[47] - Cash flows from operating activities provided $251 million in Q1 2025, down from $370 million in Q1 2024, a decrease of 32.2%[39] - Adjusted operating cash flow for Q1 2025 was $(373) million, an improvement from $(697) million in Q1 2024[57] - Adjusted free cash flow for Q1 2025 was $(578) million, an improvement from $(729) million in Q1 2024[57] Expenses and Cost Management - The company achieved a year-over-year improvement in direct operating expenses of $92 million, supported by cost control initiatives and fleet rotation[7] - Total expenses for Q1 2025 were $2,338 million, down from $2,661 million in Q1 2024, reflecting a reduction of 12.1%[35] - Vehicle depreciation decreased by 45% year-over-year, with depreciation per unit (DPU) for the quarter at $353, down from $588[10] - Depreciation of revenue earning vehicles and lease charges, net for Q1 2025 was $535 million, down from $969 million in Q1 2024[62] - Total interest expense, net for Q1 2025 was $129 million, a slight increase from $128 million in Q1 2024[56] Vehicle and Fleet Metrics - Hertz's average vehicles decreased by 8% year-over-year to 504,723, while average rentable vehicles decreased by 10% to 477,273[23] - Hertz's vehicle utilization increased by 240 basis points year-over-year to 79%[13] - The number of revenue earning vehicles increased to 13,139 units in Q1 2025, compared to 12,714 units in Q4 2024[37] - Average rentable vehicles decreased to 477,273 in Q1 2025 from 529,232 in Q1 2024[62] - Vehicle utilization improved to 75% in Q1 2025, up from 72% in Q1 2024, indicating better efficiency in fleet usage[68] - Depreciation per unit per month decreased by 14% to $265 in Q1 2025 from $308 in Q1 2024, reflecting improved cost management[68] Debt and Cash Position - The total cash and cash equivalents, along with restricted cash, decreased to $1,021 million from $1,133 million as of December 31, 2024[37] - Total assets increased to $22,047 million as of March 31, 2025, compared to $21,802 million at the end of 2024[37] - Total debt rose to $16,772 million in Q1 2025, up from $16,335 million at the end of 2024, representing an increase of 2.7%[37] - Net debt as of March 31, 2025, was $15,896 million, up from $15,355 million as of December 31, 2024[60] - The company’s accounts payable increased to $861 million in Q1 2025, up from $642 million at the end of 2024, reflecting a rise of 34.1%[37] - The company’s retained earnings showed an accumulated deficit of $2,945 million as of March 31, 2025, compared to a deficit of $2,502 million at the end of 2024[37] Strategic Initiatives - The company is on track to achieve positive Adjusted Corporate EBITDA by Q3 2025[18] - The company extended the maturity of $1.7 billion of its First Lien revolving credit facility to June 2028, enhancing its capital structure[19] - Hertz's retail vehicle sales reached a record high in Q1 2025, benefiting from tariff-driven pricing dynamics[12] - The company expects to achieve DPU below $300 faster than anticipated, now forecasted for Q2 2025[7] Revenue Generation - Total revenue per unit per month decreased to $3,792 in Q1 2025 from $3,896 in Q1 2024[62] - Total revenue per transaction day (RPD) increased to $52.07 in Q1 2025 from $51.89 in Q1 2024, indicating a stable pricing environment[68] - Average rentable vehicles decreased to 90,516 units in Q1 2025 from 95,409 units in Q1 2024, impacting overall revenue generation capacity[68]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or Commission File Number: 001-40272 OPAL FUELS INC. (Exact name of registrant as specified in its charter) Delaware 98-1578357 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) One North Lexington Avenue, Suite 1450 White Plains, Ne ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission file number 001-39982 ___________________________________ ENERGY VAULT HOLDINGS, INC. ____________________ ...

Clinical Trials and Efficacy - The pivotal trials Launch-HTN and Advance-HTN demonstrated statistically significant and clinically meaningful efficacy for lorundrostat in treating uncontrolled hypertension, with a placebo-adjusted systolic BP reduction of -9.1 mmHg at week 6 and -11.7 mmHg at week 12 for the Launch-HTN trial [99][100]. - The Launch-HTN trial enrolled 1,083 participants, with 63% having a BMI ≥30 kg/m² and 29% identifying as Black or African American, reflecting a diverse patient population [100]. - The Advance-HTN trial involved 285 participants, achieving a placebo-adjusted reduction of -7.9 mmHg in systolic BP at week 12, with 66% of subjects having a BMI ≥30 kg/m² [102]. - The company is exploring lorundrostat's potential in treating hypertension associated with chronic kidney disease (CKD) and obstructive sleep apnea (OSA), addressing multiple cardiorenal metabolic disorders [92][97]. - The FDA cleared the investigational new drug application for the Explore-OSA trial, which will evaluate lorundrostat's effects on overweight and obese subjects with moderate-to-severe OSA and hypertension [98]. - Safety data from the Launch-HTN trial indicated a low incidence of treatment-emergent serious adverse events (SAEs) at 2.2% for the 50 mg arm, supporting a favorable benefit-risk profile [104]. - The ongoing Transform-HTN trial allows subjects to continue receiving lorundrostat, generating additional long-term safety and efficacy data [92]. - The company plans to present the results of the Launch-HTN trial at the 2025 European Society of Hypertension Meeting, emphasizing its commitment to sharing clinical findings with the medical community [93]. Financial Performance and Projections - As of March 31, 2025, the company had cash, cash equivalents, and investments totaling $343.0 million [107]. - The net losses for the three months ended March 31, 2025, and 2024 were $42.2 million and $31.5 million, respectively, with an accumulated deficit of $344.7 million as of March 31, 2025 [108]. - The company has no products approved for sale and does not expect to generate revenue until lorundrostat is developed and approved [109]. - The company expects to significantly increase research and development expenses as it continues the development of lorundrostat [120]. - The company anticipates increased general and administrative expenses to support its research and development and commercialization efforts [121]. - Research and development expenses increased by $7.1 million to $37.9 million for the three months ended March 31, 2025, compared to $30.8 million in the same period of 2024 [126][127]. - General and administrative expenses rose by $2.0 million to $6.6 million for the three months ended March 31, 2025, compared to $4.6 million in the same period of 2024 [128]. - Net loss increased by $10.7 million to $42.2 million for the three months ended March 31, 2025, compared to a net loss of $31.5 million in the same period of 2024 [126]. - Net cash used in operating activities was $45.5 million for the three months ended March 31, 2025, compared to $19.1 million in the same period of 2024, reflecting an increase of $26.3 million [138]. - Net cash used in investing activities was $92.9 million for the three months ended March 31, 2025, compared to $56.0 million in the same period of 2024, an increase of $36.9 million [139]. - Net cash provided by financing activities increased to $189.3 million for the three months ended March 31, 2025, compared to $116.2 million in the same period of 2024 [140]. - The company raised approximately $700.0 million from various equity offerings since inception, including $188.7 million from a March 2025 stock sale [107][112]. - Future capital requirements will depend on various factors, including the progress of clinical trials and regulatory approvals for lorundrostat [134]. - The company anticipates continuing to incur net losses and negative cash flows from operations for the foreseeable future [130]. Obligations and Agreements - The company is obligated to pay Mitsubishi Tanabe up to $155.0 million in commercial milestone payments upon first commercial sale and meeting certain sales targets [110]. - The company entered into an ATM Equity Offering Sales Agreement with a potential offering price of up to $100 million [113]. - The company plans to use net proceeds from the private placement to fund research and development of lorundrostat and for working capital [115]. - The company has incurred no development or commercial expenses under the Mitsubishi License during the three months ended March 31, 2025, and 2024 [110]. Economic and Market Conditions - The company is exposed to interest income sensitivity due to changes in U.S. interest rates, but a hypothetical 10% change would not materially affect operations [149]. - The company contracts with vendors outside the U.S., exposing it to foreign currency exchange rate fluctuations, though these have not been significant to date [150]. - A hypothetical 10% change in foreign exchange rates would not materially impact the company's results of operations [150]. - Inflation has increased costs related to labor and research and development contracts, but has not materially impacted financial results to date [151]. - Future inflationary costs may adversely affect the company's business, financial condition, and results of operations [151]. Market Need - Approximately 120 million patients in the U.S. suffer from hypertension, with over 30 million not achieving their BP goals despite treatment, highlighting a significant unmet medical need [90]. - The company anticipates a pre-new drug application (NDA) meeting with the FDA in Q4 2025 for lorundrostat, targeting treatment for uncontrolled and resistant hypertension [91].